

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (12/97)

Approved for use through 09/30/00. CMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Underwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY
PATENT APPLICATION
TRANSMITTALnew nonprovisional applications under
37 CFR 1.53(b)

Attorney Docket No. G-1265H

First Named Inventor or Application Identifier

Jiban K. Chakrabarti, Terrence M. Hotten and
David E. Tupper

Express Mail Label No.

EL041985928US

Application Elements

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 202311. ☒ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)6. ☐ Microfiche Computer Program (Appendix)2. ☒ Specification [Total 32] [Preferred arrangement set forth below] Pages

7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claims

- a. ☐ Computer Readable Copy
- b. ☐ Paper Copy (identical to computer copy)
- c. ☐ Statement verifying identity of above copies

- Abstract of the Disclosure

ACCOMPANYING APPLICATION PARTS

3. ☐ Drawing(s) (35 USC 113) [Total] [Sheets] [Pages]8. ☐ Assignment Papers (cover sheet & document(s))4. ☐ Oath or Declaration [Total] [Pages]9. ☐ 37 CFR 3.73(b) Statement (when there is an assignee) ☐ Power of Attorneya. ☐ Newly executed (original or copy)10. ☐ English Translation Document (if applicable)b. ☒ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 37 completed) [Note Box 5 below]11. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

- 1. ☐ DELETION OF INVENTOR(S) (Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.63(b)).

12. ☒ Preliminary Amendment5. ☒ Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4a, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.13. ☒ Return Receipt Postcard (MPEP 503) (Should be specifically itemized)14. ☐ Small Entity Statement(s) ☐ Statement filed in prior application, Status still proper and desired15. ☐ Certified Copy of Priority Document(s) (if foreign priority is claimed)16. ☐ Other: XXX

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP) of prior application serial number 08/748,292, filed November 13, 1996, now allowed

18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label ☐ or Correspondence address below

NAME Arleen Palmberg

ADDRESS Eli Lilly and Company/DC 1104/AP

Lilly Corporate Center

Patent Division DC: 1104

CITY Indianapolis

STATE

Indiana

ZIP CODE

46285

COUNTRY U.S.A.

TELEPHONE

317-276-6015

FAX

317-276-2763

"Express Mail" mailing label number EL041985928US

Date of Deposit July 24, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231

OLGA M. FRANZ

Printed Name

Signature

Please type a plus sign (+) inside this box → ☐

PTO/SB/17 (12/97)

Approved for use through 09/30/00. CMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL

Note: Effective October 1, 1997.

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$1790.00)**METHOD OF PAYMENT** (check one)

1. ☒ The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:

Deposit Account Number **05-0840**Deposit Account Name **Eli Lilly and Company**

- ☒ Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17 ☐ Charge the Issue Fee Set in 37 CFR 1.18 at the Mailing of the Notice of Allowance

2. ☐ Payment Enclosed:

☐ Check ☐ Money Order ☐ Other
FEE CALCULATION**1. FILING FEE**

Large Fee Code	Entity (\$)	Small Fee Code	Entity (\$)	Fee Description	Fee Paid
101	790	201	395	Utility filing fee	790
106	330	206	165	Design filing fee	
107	540	207	270	Plant filing fee	
108	790	208	395	Reissue filing fee	
113	150	214	75	Provisional filing fee	

SUBTOTAL (1) (\$1790.00)**2. CLAIMS**

Total Claims	Extra	Fee from below	Fee Paid
2	-20=	0	X 22 = 0.00
1	-3=	0	X 82 = 0.00
Multiple Dependent Claims		X	=

Large Fee Code	Entity (\$)	Small Fee Code	Entity (\$)	Fee Description
103	22	203	11	Claims in excess of 20
102	82	202	41	Independent claims in excess of 3
104	270	204	135	Multiple dependent claim
109	82	209	41	Reissue independent claims over original patent
110	22	210	11	Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$0.00)

Complete if Known	
Application Number	Accompanying Application
Filing Date	July 24, 1998
First Named Inventor	Jiban K. Chakrabarti, et al.
Group Art Unit	
Examiner Name	
Attorney Docket Number	G-1265H

FEE CALCULATION (continued)

3. ADDITIONAL FEES	Large Fee Code	Entity (\$)	Small Fee Code	Entity (\$)	Fee Description	Fee Paid
105	130	205	65		Surcharge-late filing fee or oath	
127	50	227	25		Surcharge-late provisional filing fee or cover sheet	
139	130	139	130		Non-English specification	
147	2,520	147	2,520		For filing a request for reexamination	
112	920*	112	920*		Requesting publication of SIR prior to Examiner action	
113	1,840*	113	1,840*		Requesting publication of SIR after Examiner action	
115	110	215	55		Extension for reply within first month	
116	400	216	200		Extension for reply within second month	
117	950	217	475		Extension for reply within third month	
118	1,510	218	755		Extension for reply within fourth month	
128	2,060	228	1,030		Extension for reply within fifth month	
119	310	219	155		Notice of Appeal	
120	310	220	155		Filing a brief in support of an appeal	
121	270	221	135		Request for oral hearing	
138	1,510	138	1,510		Petition to institute a public use proceeding	
140	110	240	55		Petition to revive-unavoidable	
141	1,320	241	660		Petition to revive-unintentional	
142	1,320	242	660		Utility issue fee (or reissue)	
143	450	243	225		Design issue fee	
144	670	244	335		Plant issue fee	
122	130	122	130		Petitions to the Commissioner	
123	50	123	50		Petitions related to provisional applications	
126	240	126	240		Submission of information Disclosure Stat.	
581	40	581	40		Recording each patent assignment per property (times number of properties)	
146	790	246	395		Filing a submission after final rejection (37 CFR 1.129(a))	
149	790	249	395		For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (specify)

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$0.00)**SUBMITTED BY**Typed or Printed Name **Arlene Palmberg**Signature **Arlene Palmberg****Complete (if applicable)**Reg. Number **40,422**Date **7/24/98**"Express Mail" mailing label number **EL04105928US**Date of Deposit **July 24, 1998**

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

OLGA M. FRANZ

Printed Name

Olga M. Franz

Signature

"Express Mail" mailing label number EL041985928US

Date of Deposit July 24, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Olga M. Franz
Printed Name

Olga M. Franz
Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The Accompanying Application

Applicants : Jiban K. Chakrabarti, Terrence M. Hotten, and
David E. Tupper

For : 2-Methyl-thieno-benzodiazepine

Docket No. : G-1265H

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents

Washington, D. C. 20231

Sir:

Please amend the accompanying application as
follows:

In the Specification

Delete the title "2-Methyl-thieno-benzodiazepine"
and substitute therefore --PROCESS FOR PREPARING 2-METHYL-
THIENO-BENZODIAZEPINE--.

In the Claims

Delete Claims 1-7 and add new Claim 8.

8. A method of preparing 2-methyl-4-(4-

methyl-1-piperaziny1)-10H-thieno[2,3-b][1,5]-benzodiazepine comprising the following steps:

A.) preparing 2-amino-5-methylthiophene-3-carbonitrile by mixing sulfur, propional-dehyde in dimethyl formamide, then adding triethyl amine, then adding malononitrile;

B) preparing 2-(2-nitroanilino)-5-methylthiophene-3-carbonitrile from the reaction product of step (A) by reaction with a slurry of sodium hydride dispersed in oil in tetrahydrofuran and 2-fluoro-nitrobenze;

C) preparing 4-amino-2-methyl-10H-thiono[2,3-b][1,5]benzodiazepine hydrochloride from the reaction product of step (B) by reacting with a slurry of 2-(2-nitroanilino)-5-methyl-thiophene-3-carbonitrile in ethanol and a solution of anhydrous stannous chloride in hydrochloric acid;

D) preparing 2-methyl-4-(4-methyl-1-piperaziny1)-10H-thieno[2,3-b][1,5]benzodiazepine by refluxing the reaction product of step (C) with a mixture of N-methylpiperazine, dimethylsulphoxide and toluene.

Remarks

New Claim 8 is drawn to a process for preparing a compound of the invention. This process invention was disclosed but not claimed in all parent applications of the

instant patent application. Antecedent basis for Claim 8 is found in Example 1 of the Specification.

Summary

The Examiner is asked to enter the amendment to the specification on the claim presented herein.

Respectfully submitted,

Arleen Palmberg
Arleen Palmberg
Attorney for Applicants
Registration No. 40,422
Phone: 317-276-6015

Eli Lilly and Company
Patent Division/DC 1104/AP
Lilly Corporate Center
Indianapolis, Indiana 46285

July 24, 1998

Title

2-Methyl-thieno-benzodiazepine

Cross Reference

This application is a continuation-in-part of 08/387,997, filed February 13, 1995, now allowed, which was a continuation in part of application serial number 08/044,844, filed April 8, 1993, now abandoned, which was a continuation-in-part of pending application serial number 07/890,348, filed May 22, 1992, which issued as U.S. Patent Number 5,229,382, which was a continuation of serial number 07/690,143, filed April 23, 1991, now abandoned.

This invention relates to novel organic compounds and the use thereof as pharmaceuticals.

Currently there are many drugs available for the treatment of disorders of the central nervous system. Amongst these drugs is a category known as antipsychotics for treating serious mental conditions such as psychosis, including but not limited to schizophrenia and schizophreniform illnesses. The skilled artisan will recognize that these psychotic conditions are characterized by hallucinations, delusions, or grossly disorganized behavior which indicate that the patient suffers from gross impairment in reality testing. Drugs having said antipsychotic activity can be useful for treating a variety of important psychotic disorders.

"Express Mail" mailing label number EL0419B592845
Date of Deposit JULY 24, 1998

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

OLGA M. FRANZ

Printed Name

Olga M. Franz
Signature

The drugs available for such conditions are often associated with undesirable side effects, and there is a need for better products that control or eliminate the symptoms in a safer and more effective way. Furthermore, many patients do not respond or only partially respond to present drug treatment, and estimates of such partial- or non-responders vary between 40% and 80% of those treated.


Ever since antipsychotics were introduced it has been observed that patients are liable to suffer from drug-induced extrapyramidal symptoms which include drug-induced Parkinsonism, acute dystonic reactions, akathisia, tardive dyskinesia and tardive dystonia. The Simpson Angus Scale, Barnes Akathisia Rating Scale and Abnormal Involuntary Movement Scale (AIMS) are well known scales for assessing extrapyramidal symptoms. The great majority of drugs available for treatment of schizophrenia are prone to produce these extrapyramidal side effects when used at dosages that yield a beneficial effect on the symptoms of the disease. The severity of adverse events and/or lack of efficacy in a considerable number of patients frequently results in poor compliance or termination of treatment.

Many of the drugs are associated with a sedative effect and may also have an undesirable influence on the affective symptoms of the disease, causing depression. In some instances long term use of the drug leads to irreversible conditions, such as the tardive dyskinesia and tardive dystonia referred to *supra*.

A widely-used antipsychotic, haloperidol, is one such drug, which has been reported as causing a high incidence of extrapyramidal symptoms and may also cause tardive dyskinesia. More recently, clozapine, one of a large group of heterocyclic antipsychotics, has been introduced with the claim that it is free from extrapyramidal effects. However, the compound was found to cause agranulocytosis in some patients, a condition resulting in a lowered white blood cell count which can be

life-threatening, and it may now only be employed under very strict medical observation and supervision.

A further group of antipsychotic compounds is that described in British Patent 1 533 235. These include
5 thieno-benzodiazepines having the following structural nucleus.




The lead compound from this group, flumezapine,
10 (7-fluoro-2-methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]-benzodiazepine), was developed to the stage of being clinically administered to psychiatric patients suffering from schizophrenia. A total of 17
15 patients received treatment with flumezapine before the clinical trial was terminated after consultation with the U.S. Food and Drug Administration, because of an unacceptably high incidence of raised enzyme levels in the treated patients. The enzyme, creatinine phosphokinase
20 (CPK), and the liver enzymes, serum glutamate oxalacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT), estimated from blood samples taken from patients, were in substantial excess of normal values, indicating the possibility of toxicity. In respect of its
25 tendency to raise liver enzyme levels, flumezapine is similar to chlorpromazine, an antipsychotic which has long been in use but whose safety has been called into question.

In clinical trials with flumezapine two of the
30 patients showed the emergence of extrapyramidal side effects as measured on the AIMS scale referred to above.

We have now discovered a compound which possesses surprising and unexpected properties by comparison with flumezapine and other related compounds.

The 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine compound is of the formula



or an acid addition salt thereof. The free base of formula (I) is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine.

The 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine compound has given surprising and excellent results, described in greater detail below, in experimental screens for testing activity on the central nervous system and in clinical trials, which results suggest its usefulness for the relatively safe and effective treatment of a wide range of disorders of the central nervous system.

The results of pharmacological tests show that 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine is an antagonist of dopamine at D-1 and D-2 receptors, and in addition has antimuscarinic anticholinergic properties and antagonist activity at 5HT-2 receptor sites. It also has antagonist activity at noradrenergic α -receptors. These properties indicate that the compound is a potential neuroleptic with relaxant, anxiolytic and anti-emetic properties, and may be useful in treating psychotic conditions such as, but not limited to, schizophrenia, schizophreniform diseases and mania. At lower doses the compound is indicated for use in the treatment of mild anxiety states. The properties of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine suggest that it would be useful in

the treatment of any pathologic psychological condition, where delusions, hallucinations, disorganized behavior, or anxiety are consistent with manifestation of that pathologic condition.

5 Pathologic psychological conditions which are psychoses or may be associated with psychotic features include, but are not limited to the following disorders which have been characterized in the DSM-III-R. Diagnostic and Statistical Manual of Mental Disorders, Revised, 3rd
10 Ed. (1980). The DSM-III-R was prepared by the Task Force on Nomenclature and Statistics of the American Psychiatric Association, and provides clear descriptions of diagnostic categories. The numbers in parenthesis refer to the DSM-III-R categories. The skilled artisan will recognize that
15 there are alternative nomenclatures, nosologies, and classification systems for pathologic psychological conditions and that these systems evolve with medical scientific progress.

20 Examples of pathologic psychological conditions which may be treated using 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine include, but are not limited to, Moderate Mental Retardation (318.00), Severe Mental Retardation (318.10), Profound Mental Retardation (318.20), Unspecified Mental Retardation
25 (319.00), Autistic disorder (299.00), Pervasive Development Disorder NOS (299.80), Attention-deficit Hyperactivity Disorder (314.01), Conduct Disorder, Group Type (312.20), Conduct Disorder, Solitary Aggressive Type (312.00), Conduct Disorder, Undifferentiated Type (312.90), Tourette's Disorder (307.23), Chronic Motor Or Vocal Tic Disorder (307.22),
30 Transient Tic Disorder (307.21), Tic Disorder NOS (307.20), Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delirium (290.30), Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Delusions (290.20),
35 Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, with Depression (290.21), Primary Degenerative Dementia of the Alzheimer Type, Senile Onset, Uncomplicated

(290.00), Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delirium (290.11), Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Delusions (290.12), Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, with Depression (290.13), Primary Degenerative Dementia of the Alzheimer Type, Presenile Onset, Uncomplicated (290.10), Multi-infarct dementia, with Delirium (290.41), Multi-infarct dementia, with Delusions (290.42), Multi-infarct dementia, with Depression (290.43), Multi-infarct dementia, Uncomplicated (290.40), Senile Dementia NOS (290.00), Presenile Dementia NOS (290.10), Alcohol Withdrawal Delirium (291.00), Alcohol Hallucinoses (291.30), Alcohol Dementia Associated with Alcoholism (291.20), Amphetamine or Similarly Acting Sympathomimetic Intoxication (305.70), Amphetamine or Similarly Acting Sympathomimetic Delirium (292.81), Amphetamine or Similarly Acting Sympathomimetic Delusional Disorder (292.11), Cannabis Delusional Disorder (292.11), Cocaine Intoxication (305.60), Cocaine Delirium (292.81), Cocaine Delusional Disorder (292.11), Hallucinogen Hallucinoses (305.30), Hallucinogen Delusional Disorder (292.11), Hallucinogen Mood Disorder (292.84), Hallucinogen Posthallucinogen Perception Disorder (292.89), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Intoxication (305.90), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delirium (292.81), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Delusional Disorder (292.11), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Mood Disorder (292.84), Phencyclidine (PCP) or Similarly Acting Arylcyclohexylamine Organic Mental Disorder NOS (292.90), Other or Unspecified Psychoactive Substance Intoxication (305.90), Other or Unspecified Psychoactive Substance Delirium (292.81), Other or Unspecified Psychoactive Substance Dementia (292.82), Other or Unspecified Psychoactive Substance Delusional Disorder (292.11), Other or Unspecified Psychoactive Substance Hallucinoses (292.12), Other or Unspecified Psychoactive

- Substance Mood Disorder (292.84), Other or Unspecified Psychoactive Substance Anxiety Disorder (292.89), Other or Unspecified Psychoactive Substance Personality Disorder (292.89), Other or Unspecified Psychoactive Substance Organic Mental Disorder NOS (292.90), Delirium (293.00), Dementia (294.10), Organic Delusional Disorder (293.81), Organic Hallucinosiis (293.82), Organic Mood Disorder (293.83), Organic Anxiety Disorder (294.80), Organic Personality Disorder (310.10), Organic Mental Disorder (294.80),
- 5 Obsessive Compulsive Disorder (300.30), Post-traumatic Stress Disorder (309.89), Generalized Anxiety Disorder (300.02), Anxiety Disorder NOS (300.00), Body Dysmorphic Disorder (300.70), Hypochondriasis (or Hypochondriacal Neurosis) (300.70), Somatization Disorder (300.81), Undifferentiated
- 10 Somatoform Disorder (300.70), Somatoform Disorder NOS (300.70), Intermittent Explosive Disorder (312.34), Kleptomania (312.32), Pathological Gambling (312.31), Pyromania (312.33), Trichotillomania (312.39), and Impulse Control Disorder NOS (312.39).
- 15 Schizophrenia, Catatonic, Subchronic, (295.21), Schizophrenia, Catatonic, Chronic (295.22), Schizophrenia, Catatonic, Subchronic with Acute Exacerbation (295.23), Schizophrenia, Catatonic, Chronic with Acute Exacerbation (295.24), Schizophrenia, Catatonic, in Remission (295.55),
- 20 Schizophrenia, Catatonic, Unspecified (295.20), Schizophrenia, Disorganized, Subchronic (295.11), Schizophrenia, Disorganized, Chronic (295.12), Schizophrenia, Disorganized, Subchronic with Acute Exacerbation (295.13), Schizophrenia, Disorganized, Chronic with Acute Exacerbation
- 25 (295.14), Schizophrenia, Disorganized, in Remission (295.15), Schizophrenia, Disorganized, Unspecified (295.10), Schizophrenia, Paranoid, Subchronic (295.31), Schizophrenia, Paranoid, Chronic (295.32), Schizophrenia, Paranoid, Subchronic with Acute Exacerbation (295.33), Schizophrenia,
- 30 Paranoid, Chronic with Acute Exacerbation (295.34), Schizophrenia, Paranoid, in Remission (295.35), Schizophrenia, Paranoid, Unspecified (295.30), Schizophrenia,
- 35

Undifferentiated, Subchronic (295.91), Schizophrenia, Undifferentiated, Chronic (295.92), Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation (295.93), Schizophrenia, Undifferentiated, Chronic with Acute Exacerbation (295.94), Schizophrenia, Undifferentiated, in Remission (295.95), Schizophrenia, Undifferentiated, Unspecified (295.90), Schizophrenia, Residual, Subchronic (295.61), Schizophrenia, Residual, Chronic (295.62), Schizophrenia, Residual, Subchronic with Acute Exacerbation (295.63), Schizophrenia, Residual, Chronic with Acute Exacerbation (295.94), Schizophrenia, Residual, in Remission (295.65), Schizophrenia, Residual, Unspecified (295.60), Delusional (Paranoid) Disorder (297.10), Brief Reactive Psychosis (298.80), Schizophreniform Disorder (295.40), Schizoaffective Disorder (295.70), Induced Psychotic Disorder (297.30), Psychotic Disorder NOS (Atypical Psychosis) (298.90), Bipolar Disorder, Mixed, Severe, without Psychotic Features (296.63), Bipolar Disorder, Manic, Severe, without Psychotic Features (296.43), Bipolar Disorder, Depressed, Severe, without Psychotic Features (296.53), Major Depression, Single Episode, Severe, without Psychotic Features (296.23), Major Depression, Recurrent, Severe, without Psychotic Features (296.33), Bipolar Disorder, Mixed, with Psychotic Features (296.64), Bipolar Disorder, Manic, with Psychotic Features (296.44), Bipolar Disorder, Depressed, with Psychotic Features (296.54), Bipolar Disorder NOS (296.70), Major Depression, Single Episode, with Psychotic Features (296.24), Major Depression, Recurrent with Psychotic Features (296.34) Personality Disorders, Paranoid (301.00), Personality Disorders, Schizoid (301.20), Personality Disorders, Schizotypal (301.22), Personality Disorders, Antisocial (301.70), and Personality Disorders, Borderline (301.83).

Preferably, an effective amount of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof, is used for the treatment of Moderate Mental Retardation;

Severe Mental Retardation; Profound Mental Retardation;
Autistic disorder; Pervasive Development Disorder NOS;
Conduct Disorder, Group Type; Conduct Disorder, Solitary
Aggressive Type; Tourette's Disorder; Primary Degenerative
5 Dementia of the Alzheimer Type, Senile Onset, with
Delirium; Primary Degenerative Dementia of the Alzheimer
Type, Senile Onset, with Delusions; Schizophrenia,
Catatonic, Subchronic; Schizophrenia, Catatonic, Chronic;
Schizophrenia, Catatonic, Subchronic with Acute
10 Exacerbation; Schizophrenia, Catatonic, Chronic with Acute
Exacerbation; Schizophrenia, Catatonic, in Remission;
Schizophrenia, Catatonic, Unspecified; Schizophrenia,
Disorganized, Subchronic; Schizophrenia, Disorganized,
Chronic; Schizophrenia, Disorganized, Subchronic with Acute
15 Exacerbation; Schizophrenia, Disorganized, Chronic with
Acute Exacerbation; Schizophrenia, Disorganized, in
Remission; Schizophrenia, Disorganized, Unspecified;
Schizophrenia, Paranoid, Subchronic; Schizophrenia,
Paranoid, Chronic; Schizophrenia, Paranoid, Subchronic with
20 Acute Exacerbation; Schizophrenia, Paranoid, Chronic with
Acute Exacerbation; Schizophrenia, Paranoid, in Remission;
Schizophrenia, Paranoid, Unspecified; Schizophrenia,
Undifferentiated, Subchronic; Schizophrenia,
Undifferentiated, Chronic; Schizophrenia, Undifferentiated,
25 Subchronic with Acute Exacerbation; Schizophrenia,
Undifferentiated, Chronic with Acute Exacerbation;
Schizophrenia, Undifferentiated, in Remission;
Schizophrenia, Undifferentiated, Unspecified;
Schizophrenia, Residual, Subchronic; Schizophrenia,
30 Residual, Chronic; Schizophrenia, Residual, Subchronic with
Acute Exacerbation; Schizophrenia, Residual, Chronic with
Acute Exacerbation; Schizophrenia, Residual, in Remission;
Schizophrenia, Residual, Unspecified; Delusional (Paranoid)
Disorder; Brief Reactive Psychosis; Schizophreniform
35 Disorder; Schizoaffective Disorder; Induced Psychotic
Disorder; Psychotic Disorder NOS (Atypical
Psychosis); Bipolar Disorder, Mixed, with Psychotic

Features; Bipolar Disorder, Manic, with Psychotic Features;
Bipolar Disorder, Depressed, with Psychotic Features;
Bipolar Disorder NOS; Major Depression, Single Episode,
with Psychotic Features; Personality Disorders, Paranoid;
5 Personality Disorders, Schizoid; Personality Disorders,
Schizotypal; Personality Disorders, Antisocial; Personality
Disorders, Borderline; Hebephrenic Schizophrenia; Post-
Schizophrenic Depression; Delusional Disorder; and Other
Persistent Delusional Disorders.

10 More preferredly, 2-methyl-4-(4-methyl-1-
piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine is used
to treat the following pathologic psychological conditions
including Schizophrenia, Catatonic, Subchronic;
Schizophrenia, Catatonic, Chronic; Schizophrenia,
15 Catatonic, Subchronic with Acute Exacerbation;
Schizophrenia, Catatonic, Chronic with Acute Exacerbation;
Schizophrenia, Catatonic, in Remission; Schizophrenia,
Catatonic, Unspecified; Schizophrenia, Disorganized,
Subchronic; Schizophrenia, Disorganized, Chronic;
20 Schizophrenia, Disorganized, Subchronic with Acute
Exacerbation; Schizophrenia, Disorganized, Chronic with
Acute Exacerbation; Schizophrenia, Disorganized, in
Remission; Schizophrenia, Disorganized, Unspecified;
Schizophrenia, Paranoid, Subchronic; Schizophrenia,
25 Paranoid, Chronic; Schizophrenia, Paranoid, Subchronic with
Acute Exacerbation; Schizophrenia, Paranoid, Chronic with
Acute Exacerbation; Schizophrenia, Paranoid, in Remission;
Schizophrenia, Paranoid, Unspecified; Schizophrenia,
Undifferentiated, Subchronic; Schizophrenia,
30 Undifferentiated, Chronic; Schizophrenia, Undifferentiated,
Subchronic with Acute Exacerbation; Schizophrenia,
Undifferentiated, Chronic with Acute Exacerbation;
Schizophrenia, Undifferentiated, in Remission;
Schizophrenia, Undifferentiated, Unspecified;
35 Schizophrenia, Residual, Subchronic; Schizophrenia,
Residual, Chronic; Schizophrenia, Residual, Subchronic with
Acute Exacerbation; Schizophrenia, Residual, Chronic with

Acute Exacerbation; Schizophrenia, Residual, in Remission; Schizophrenia, Residual, Unspecified; Delusional (Paranoid) Disorder; Brief Reactive Psychosis; Schizophreniform Disorder; Schizoaffective Disorder; Induced Psychotic Disorder; Psychotic Disorder NOS (Atypical Psychosis); Bipolar Disorder, Mixed, with Psychotic Features; Bipolar Disorder, Manic, with Psychotic Features; Bipolar Disorder, Depressed, with Psychotic Features; Bipolar Disorder NOS; Major Depression, Single Episode, with Psychotic Features; Personality Disorders, Paranoid; Personality Disorders, Schizoid; Personality Disorders, Schizotypal; Personality Disorders, Antisocial; Personality Disorders, Borderline; Hebephrenic Schizophrenia; Post-Schizophrenic Depression; Delusional Disorder; and Other Persistent Delusional Disorders.

Examples of conditions which are most preferredly treated using 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine include Schizophrenia, Catatonic, Subchronic; Schizophrenia, Catatonic, Chronic; Schizophrenia, Catatonic, Subchronic with Acute Exacerbation; Schizophrenia, Catatonic, Chronic with Acute Exacerbation; Schizophrenia, Catatonic, in Remission; Schizophrenia, Catatonic, Unspecified; Schizophrenia, Disorganized, Subchronic; Schizophrenia, Disorganized, Chronic; Schizophrenia, Disorganized, Subchronic with Acute Exacerbation; Schizophrenia, Disorganized, Chronic with Acute Exacerbation; Schizophrenia, Disorganized, in Remission; Schizophrenia, Disorganized, Unspecified; Schizophrenia, Paranoid, Subchronic; Schizophrenia, Paranoid, Chronic; Schizophrenia, Paranoid, Subchronic with Acute Exacerbation; Schizophrenia, Paranoid, Chronic with Acute Exacerbation; Schizophrenia, Paranoid, in Remission; Schizophrenia, Paranoid, Unspecified; Schizophrenia, Undifferentiated, Subchronic; Schizophrenia, Undifferentiated, Chronic; Schizophrenia, Undifferentiated, Subchronic with Acute Exacerbation; Schizophrenia,

Undifferentiated, Chronic with Acute Exacerbation;
Schizophrenia, Undifferentiated, in Remission;
Schizophrenia, Undifferentiated, Unspecified;
Schizophrenia, Residual, Subchronic; Schizophrenia,
5 Residual, Chronic; Schizophrenia, Residual, Subchronic with
Acute Exacerbation; Schizophrenia, Residual, Chronic with
Acute Exacerbation; Schizophrenia, Residual, in Remission;
Schizophrenia, Residual, Unspecified; Delusional (Paranoid)
Disorder; Brief Reactive Psychosis; Schizophreniform
10 Disorder; Schizoaffective Disorder; Personality Disorders,
Schizoid; Personality Disorders, Schizotypal; Hebephrenic
Schizophrenia; and Post-Schizophrenic Depression.

Examples of anxiety disorders which may more
preferredly be treated using an effective amount of 2-
15 methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b]-
[1,5]benzodiazepine, or an acid addition salt thereof,
include Psychoactive Substance Anxiety Disorder; Organic
Anxiety Disorder; Obsessive Compulsive Disorder; Post-
traumatic Stress Disorder; Generalized Anxiety Disorder;
20 and Anxiety Disorder NOS.

Examples of the anxiety disorders which are most
preferredly treated using 2-methyl-4-(4-methyl-1-
piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine include
Organic Anxiety Disorder; Obsessive Compulsive Disorder;
25 Post-traumatic Stress Disorder; Generalized Anxiety
Disorder; and Anxiety Disorder NOS.

As mentioned above, 2-methyl-4-(4-methyl-1-
piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine has shown
a high level of activity in the clinical evaluation of
30 psychiatric patients suffering from schizophrenia, and it
exhibits this high activity at surprisingly low dosage
levels. The dosage levels have been found to be lower than
would be expected from observations of the compound made in
initial tests on animal models. Its response profile in
35 patients follows that of known antipsychotic agents when
they have been used successfully, there being a clear
similarity between the performance of the compound and that

of known antipsychotic agents in its ratings on the major assessment scales such as Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression (CGI).

In the first completed open (as opposed to blind) study of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine in schizophrenic patients, six out of eight patients who completed at least 2 weeks of treatment showed between 66% and 87% improvement at 4 weeks, as assessed on BPRS scale, at daily dosages between 5 and 30 mg. Preliminary results from a further three ongoing clinical trials now appear to confirm this high level of efficacy and at doses lower than or at the low end of the dosage level used in the first study, for example, at 2.5 and 5 mg per day.

Moreover, although some patients have exhibited increases in hepatic enzyme levels, no patient treated to date has experienced clinically significant hepatic disease. Plasma levels of creatinine phosphokinase (CPK) are lower than with flumazenil, indicating a lower adverse effect on muscular tissue. Furthermore, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine causes lower elevation of prolactin levels than other currently used neuroleptic drugs and this suggests fewer disturbances of the menstrual cycle, and less gynecomastia and galactorrhea. No substantial clinically significant alteration of white blood cell count has been observed in clinical studies.

In dog toxicity studies with a closely analogous compound, 2-ethyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, at a dosage of 8 mg/kg, it was observed that four out of eight dogs showed a significant rise in cholesterol levels, whereas 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine did not show any rise in cholesterol levels.


Overall, therefore, in clinical situations, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b]-

[1,5]benzodiazepine shows marked superiority, and a better side effects profile than prior known antipsychotic agents, and has a highly advantageous activity level.


The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine can be used both in its free base and acid addition salt forms. The acid addition salts are preferably the pharmaceutically acceptable, non-toxic addition salts with suitable acids, such as those of inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or of organic acids, such as organic carboxylic acids, for example glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric or lactic acid, or organic sulphonic acids for example methane sulphonic, ethane sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic or naphthalene-2-sulphonic acid. In addition to pharmaceutically acceptable acid addition salts, other acid addition salts are included in the invention, for example, those with picric or oxalic acid, since they have potential to serve as intermediates in purification or in the preparation of other, for example, pharmaceutically acceptable, acid addition salts, or are useful for identification, characterization or purification of the free base.

According to a further aspect of the invention there is provided a process for producing a compound of formula (I) or an acid addition salt thereof, which comprises

(a) reacting N-methylpiperazine with a compound of the formula




in which Q is a radical capable of being split off, or
(b) ring-closing a compound of the formula




Appropriate reaction conditions and suitable values of Q can readily be chosen for these processes.

In reaction (a) the radical Q can, for example, be an amino group or a mono- or dialkyl-substituted amino group (each alkyl substituent suitably containing 1 to 4 carbon atoms), hydroxyl, thiol, or an alkoxy, alkylthio or alkylsulphonyl group suitably containing 1 to 4 carbon atoms, for example a methoxy or methylthio group, or a halogen atom, especially a chlorine atom. Preferably, Q is amino ($-NH_2$), hydroxyl or thiol, and amino is most preferred. The reaction is preferably carried out at a temperature of from $50^\circ C$ to $200^\circ C$.

When Q is amino, the intermediate of formula (II) may also exist in the imino form:




and when Q is hydroxyl or thiol, the intermediates of formula (II) may exist in their amide and thioamide forms:




The amidine of formula (II) (Q is -NH_2), can be in salt form, for example a salt of a mineral acid such as the hydrochloride, and can be reacted with N-methylpiperazine in an organic solvent such as anisole, toluene, dimethylformamide or dimethyl-sulphoxide, preferably at a temperature range of 100 to 150°C.

The amidine is prepared by condensing a thiophene compound of formula



with an ortho-halonitrobenzene, in the presence of a base, for example sodium hydride, in a solvent such as tetrahydrofuran or n-butyl lithium in tetrahydrofuran, or potassium carbonate or lithium hydroxide in dimethylsulphoxide or aqueous sodium hydroxide in dimethylsulfoxide, or with a tetraalkyl-ammonium salt in a two-phase system, to form a nitronitrile of formula:




which can be simultaneously reduced and ring-closed to the amidine of formula (II) employing, for example, stannous chloride and hydrogen chloride in aqueous ethanol or, alternatively by reduction with hydrogen and palladium/carbon or ammonium polysulphide followed by acid-catalysed ring closure. The intermediate of formula (IIa) may be isolated using ammonium chloride (NH_4Cl) or ammonium acetate (NH_4OAc).

When Q is hydroxyl, reaction (a) is preferably carried out in the presence of titanium tetrachloride which has the ability to react with the N-methylpiperazine to form a metal amine complex. Other metal chlorides such as those of zirconium, hafnium or vanadium may also be employed. The reaction can be carried out in the presence of an acid binding agent such as a tertiary amine, for example, triethylamine.

Alternatively, the reaction can be carried out using excess of N-methylpiperazine to act as an acid-binding agent. A suitable organic solvent such as toluene or chlorobenzene can be used as a reaction medium, although the use of anisole is particularly desirable, at least as a co-solvent, in view of its ability to form a soluble complex with $TiCl_4$.

If desired, elevated temperatures, for example up to $200^{\circ}C$, can be used to hasten the reaction and a preferred temperature range for carrying out the reaction is from $80^{\circ}C$ to $120^{\circ}C$.

The intermediate amide of formula (II) (Q is -OH) can be prepared from the corresponding amidine (Q is $-NH_2$) by alkaline hydrolysis, or can be derived from compounds of formula



in which R is an ester group, preferably C₁-4 alkyl, by ring closure employing, for example, sodium methylsulphinyll methanide in a suitable solvent such as dimethylsulphoxide. Alternatively, the amide can be prepared by ring closure of an amino-acid, employing for example dicyclohexylcarbodiimide (DCC) in a suitable solvent such as tetrahydrofuran. The amino-acid can be obtained for

example from the above esters by basic hydrolysis using for example sodium hydroxide in ethanol.


Thioamides of formula (II) (Q is -SH), iminothio-ethers, iminoethers or iminohalides, or other derivatives containing active Q radicals as specified above, tend to be more reactive towards N-methylpiperazine and can usually be reacted without the necessity for the presence of TiCl_4 , but otherwise employing the same conditions of temperature and solvent.

The thioamide of formula (II) (Q is -SH) can be prepared by treating a solution of the corresponding amide in an anhydrous basic solvent, such as pyridine, with phosphorous pentasulphide. Similarly, the amide can be converted to the iminothioether, iminoether or iminohalide, or other derivatives containing active Q radicals, by treatment with conventional reagents such as for example in the case of the iminochloride, phosphorous pentachloride.

The intermediate compounds of formula (II) in which Q is a radical capable of being split off, particularly those in which Q is $-\text{NH}_2$, $-\text{OH}$ or $-\text{SH}$ and when Q is $-\text{NH}_2$ salts thereof, are novel compounds, and form a further aspect of the present invention.


With regard to reaction (b) above, the compound of formula (III) may be ring-closed by employing, for example, titanium tetrachloride as catalyst and anisole as solvent, and the reaction is preferably carried out at a temperature of 100°C to 250°C , for example from 150°C to 200°C .

The intermediate compound of formula (III) is preferably prepared in situ without isolation by reacting a compound of formula




in which R is an ester group, preferably C₁₋₄ alkyl, with N-methylpiperazine, by heating to a temperature of between 30°C and 120°C, for example about 100°C, in a suitable solvent such as for example anisole, and employing TiCl₄ as catalyst.

The compound of formula (IV) can be prepared from the corresponding nitro compound of formula



Such compounds of formula (V) in which R is an ester group, such as for example C₁₋₄ alkyl, are novel and form a further aspect of the invention.

If convenient this nitro compound can be converted to the amine of formula (IV) without isolation, before reaction with N-methylpiperazine. Intermediate compounds of formula (V) can be made by condensation of a thiophene of formula



with an ortho-halonitrobenzene, preferably ortho fluoro- or chloro- nitrobenzene, in the presence of a base, for example, (a) sodium hydride in a solvent such as for example tetrahydrofuran and at a temperature of from -20°C to 30°C, or (b) anhydrous potassium carbonate or lithium hydroxide in a solvent such as dimethylsulphoxide at a temperature of from 90°C to 120°C. The compound of formula (V) is converted to that of formula (IV) by reduction, for

example catalytically, employing hydrogen and palladium/carbon, or chemically, employing stannous chloride and hydrogen chloride in aqueous ethanol, or ammonium polysulphide, or zinc in aqueous ammonium chloride.

It will be appreciated that the compound of formula (I) may be isolated per se or may be converted to an acid addition salt using conventional methods.

As mentioned above, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine has useful central nervous system activity. This activity has been demonstrated in models using well-established procedures. For example, the compound has been assessed in a number of standard behavioral tests predictive of antipsychotic activity. It antagonized apomorphine-induced climbing behavioral and hypothermia in mice (Moore, N.A. et al. Psychopharmacology 24 (2), 263-266 (1988), and 96, 539 (1988)) at doses of less than 10 mg/kg. The compound also inhibited a conditioned avoidance response in rats (ED₅₀ 4-7 mg/kg), but unlike standard compounds, it induced catalepsy only at much higher doses (ED₅₀ 39.4 mg/kg). This separation between the doses required to block a conditioned avoidance response and to induce catalepsy indicates that the compound is less likely to induce extrapyramidal side effects in the clinic.

The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine was also active at doses of less than 10 mg/kg in a test based on the apomorphine-induced climbing test referred to above, which measured the ability of the compound to prevent the disruption of climbing response produced by 24 hour pre-treatment with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), a dopamine receptor inactivating agent (Meller et al. Central D1 dopamine receptors, Plenum Press, 1988). This test shows that the compound possesses activity at both the D-1 and D-2 receptors.

The 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine compound was active in the multiple conflict schedule at doses of less than 5 mg/kg. Moore, Nicholas A. et al., The Journal of Pharmacology and Experimental Therapeutics, 545-551, 262:2 (1992). The test measures characteristic changes in rates of responding associated with anxiolytic agents. The conflict procedure results are indicative of favorable anxiolytic activity.

The conflict procedure used was based on the method of Geller and Seifter, Psychopharmacologia 1: 482-492, (1960). Rats were trained on a multiple schedule consisting of three components. Individual components were as follows: 1) for 9 minutes, lever pressing was reinforced on a variable interval 30 second schedule (VI 30, reward). This period was signaled by illumination of the houselight alone. 2) During the following 3-minute period, lever presses were recorded but had no programmed consequence (time-out). 3) Lever pressing was reinforced according to a fixed ratio 10 second food presentation (FR10) for 3 minutes; however, each reinforced response was accompanied by an electric current (0.5 mA) being applied to the grid floor for 500 msec (conflict). This component was signaled by illumination of the houselight and three cue lights on the front panel. This sequence of three components (reward/time-out/conflict) was presented twice in the same order during the daily 30 minute session. Animals were given extensive training on this schedule until the following criteria had been satisfied: 1) rates of responding during the individual VI30 components did not differ by more than 10%; 2) rates of responding during time-out and conflict were less than 10% of the rate during the VI component; and 3) the above criteria were satisfied for a period of five days.

After the training procedure, drug testing was initiated. During this period, the animals were dosed orally with either test compounds or vehicle in a randomized order 60 minutes before testing. At least two

drug-free training days occurred between test sessions. This test indicates that the compound has anxiolytic properties which are not observed with typical antipsychotic agents. Spealman et al., J. Pharmacol. Exp. Ther., 212:435-440, 1980.

In addition, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine has been found to have a favorable profile of activity in a number of in vitro binding assays, designed to measure the degree of binding to neural receptors.

In keeping with the observations made in the behavioral tests, the compound is active at both the dopamine D-1 and D-2 receptors as indicated by an IC₅₀ of less than 1 μ M in the ³H-SCH23390 (Billard, W. et al. Life Sciences 35 1885 (1984)) and the ³H-spiperone (Seeman, P. et al. Nature 261 717 (1976)) binding assays respectively.

The compound has an IC₅₀ of less than 1 μ M in the ³H-QNB binding assay described by Yamamura, HI and Snyder, SH in Proc.Nat.Acad.Sci. USA 71 1725 (1974) indicating that it has antimuscarinic-anticholinergic activity. In addition, the compound shows its greatest activity at the 5-HT-2 receptor in that it displaces H-spiperone from binding sites in the rat frontal cortex (Peroutka, SJ and Snyder, SH Mol. Pharmacol. 16 687 (1979)) at low nanomolar concentrations. The compound is also active at the 5-HT-1C receptor.

This profile of activity in in vitro receptor binding assays, like that observed in the behavioral tests, would indicate that the compound is effective in the treatment of psychotic conditions but is less likely to induce extrapyramidal side-effects. The behavioral tests and in vitro binding assays indicate that the compound is an effective anxiolytic agent and is useful for the treatment of other pathologic psychological conditions.

The 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine compound is effective over a wide dosage range, the actual dose administered being

dependent on the condition being treated. For example, in the treatment of adult humans, dosages of from 0.25 to 30 mg, preferably from 1 to 20 mg, per day may be used. A once a day dosage is normally sufficient, although divided doses may be administered. For treatment of psychotic disorders a dose range of from 1 to 20 mg, preferably 2.5 to 15 mg per day is suitable, whereas for mild anxiety states a lower dosage range, such as from 0.25 to 5 mg, preferably 1 to 5 mg, may be more appropriate. In choosing a suitable regimen for patients suffering from psychotic illness it may frequently be necessary to begin with a dosage of from 1 to 20 mg per day and when the illness is under control to reduce to a dosage as low as 1 mg per day. In studies using radiolabelled compound of the invention, residues have been detected in the saliva and thus the compound can potentially be monitored in patients to assess compliance.

The 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine compound will normally be administered orally or by injection and, for this purpose, it is usually employed in the form of a pharmaceutical composition.

Accordingly the invention includes a pharmaceutical composition comprising as active ingredient a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable carrier. In making the compositions of the invention conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. The active ingredient can be adsorbed on a granular solid container for example in a sachet. Some

examples of suitable carriers are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, syrup, methyl cellulose, methyl- and propyl-hydroxy-benzoate, talc, magnesium stearate or mineral oil. The compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient.

Depending on the method of administration, the compositions may be formulated as tablets, granules, capsules, depot formulation, injection solutions for parenteral use, gel or suspension for transdermal delivery, suspensions or elixirs for oral use or suppositories. Preferably the compositions are formulated in a dosage unit form, each dosage containing from 0.25 to 30 mg, more usually 1 to 20 mg, of the active ingredient. A preferred formulation of the invention is a capsule or tablet comprising 0.25 to 30 mg or 1 to 20 mg of active ingredient together with a pharmaceutically acceptable carrier therefor. A more preferred formulation is a tablet comprising 1, 2.5, 5, 7.5 or 10 mg of active ingredient together with a pharmaceutically acceptable carrier therefor. A further preferred formulation is an injection which in unit dosage form comprises 0.25 to 30 mg or 1 to 20 mg of active ingredient together with a pharmaceutically acceptable diluent therefor. A type of injection formulation that is especially desirable is a sustained release formulation for intra-muscular injection. Another preferred formulation is a granule formulation. The granule formulation may serve as a reconstitutable solid.

The invention is illustrated by the following Examples.

EXAMPLE 11. 2-Amino-5-methylthiophene-3-carbonitrile

A mixture of sulfur (217.8 g, 6.79 mol), propional-dehyde (472.5 g, 587 mL, 8.13 mol) and dimethylformamide (1350 mL) was placed in a 5 litre flange-necked flask fitted with air stirrer, air condenser, long reach thermometer and dropping funnel. Triethylamine (576 mL, 4.13 mol) was added dropwise over 30 minutes to the cooled stirred reaction mixture whilst maintaining the pot temperature between 5-10°C with an ice-bath. After addition was complete the pot was allowed to warm up to 18°C over 50 minutes, keeping the mixture well stirred. Then a solution of malononitrile (450 g, 6.8 mol) in dimethylformamide (900 mL) was added dropwise over 70 minutes keeping the pot temperature around 20°C throughout the addition. After addition was complete the mixture was stirred at 15-20°C for a further 45 minutes then sampled for TLC. The mixture was then poured onto ice (4 litres)/water (8 litres) with stirring and this caused the required product to precipitate. After 10 minutes the stirrer was switched off and the solid allowed to settle. The aqueous liquor was decanted away and the solid isolated by filtration. The isolated solid was well washed with water (de-ionized, 4 litres), then dried over night in vacuo at 70-75°C to give the title compound (585 g), m.p. 100°C.

2. 2-(2-Nitroanilino)-5-methylthiophene-3-carbonitrile

To a stirred slurry of sodium hydride (14.4 g, 50% dispersion in oil, 0.3 mol) in dry tetrahydrofuran (50 mL) under nitrogen was added, dropwise, a solution of 2-fluoro-nitrobenzene (28.2 g, 0.2 mol) and 2-amino-5-methylthiophene-3-carbonitrile (27.6 g, 0.2 mol) in dry tetrahydrofuran (250 mL). The mixture was stirred at 25°C for 24 hours, poured onto cracked ice and extracted into dichloromethane (3 x 500 mL). The combined extracts were

washed with 2N hydrochloric acid (2 x 200 mL), water (2 x 200 mL), dried over magnesium sulfate and the solvent removed under reduced pressure. The residue was crystallized from ethanol to give the title compound, (35.2 g), m.p. 99-102°C.


3. 4-Amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine, hydrochloride

To a stirred slurry of 2-(2-nitroanilino)-5-methyl-thiophene-3-carbonitrile (3 g, 0.011 mol) in ethanol (35 mL) at 50°C was added, over 10 minutes, a solution of anhydrous stannous chloride (6.95 g, 0.037 mol) in hydrochloric acid (26 mL, 5M). The mixture was stirred under reflux for 1 hour, concentrated under reduced pressure and allowed to crystallize over night at 5°C. The salt was filtered, washed with a small amount of water, dried (4.3 g) m.p. >250°C, and used without further purification in the next stage.

4. 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]-benzodiazepine

Crude 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzo-diazepine, hydrochloride (4.3 g) was refluxed in a mixture of N-methylpiperazine (15 mL), dimethylsulphoxide (20 mL) and toluene (20 mL) under a nitrogen atmosphere for 20 hours. The mixture was cooled to ca. 50°C, water (20 mL) added, and the product allowed to crystallize at 5°C over night. The product was filtered and crystallized from acetonitrile (30 mL) to give the title compound (1.65g) m.p. 195°C.

The structure of the compound was confirmed spectroscopically:



^1H NMR (CDCl_3): δ 2.30 (3H, s, 4'- CH_3), 2.28 (3H, s, 2- CH_3), 2.45 (4H, m, 3'- CH_2) 3.49 (4H, m, 2'- CH_2), 5.00 (H, broad s, 10-NH), 6.23 (H, broad s, 3-CH), 6-35-7-10 (4H, m, 6,7,8,9-H).

^{13}C NMR (CDCl_3): δ 128.5 (s, C-2), 127.8 (d, C-3), 119.1 (s, C-3a), 157.4 (s, C-4) 140.8 (s, C-5a), 123.4, 122.6, 124.1 (d, C-6,7,8), 118.8 (d, C-9), 142.5 (s, C-9a), 151.8 (s, C-10a), 46.5 (t, 2'-C), 54.8 (t, 3'-C) 45.9 (q, -4'-C), 15.2 (q, 2-Me).

Mass spectra shows an M^+ of 312 and major fragment ions of m/z 255, 242, 229 and 213.

EXAMPLE 2

1. Methyl 2-amino-5-methylthiophene-3-carboxylate

To a stirred mixture of methyl cyanoacetate (3.9 g, 0.04 mol), sulfur (1.26 g, 0.04 mol) and triethylamine (3.2 mL, 0.02 mol) in dry methylformamide (12 mL) under a nitrogen atmosphere at 45°C was added, dropwise, a solution of freshly distilled propionaldehyde (2.5 g, 0.043 mol) in dry dimethylformamide (2 mL), keeping the temperature at $45-47^\circ\text{C}$. The mixture was stirred at 45°C for 1.5 hours, then partitioned between water and ethyl acetate. The organic extract was washed with water, dried and evaporated. The title compound was purified by chromatography on neutral alumina, eluting with chloroform-hexane (4.8 g).

2. Methyl 2-(2-nitroanilino)-5-methylthiophene-3-carboxylate

To a stirred suspension of sodium hydride (2 g) in dry tetrahydrofuran (25 mL) under a nitrogen atmosphere was added a solution of methyl 2-amino-5-methylthiophene-3-carboxylate (4.8 g, 0.028 mol) and 2-fluoronitrobenzene (4.0 g, 0.025 mol) in dry tetrahydrofuran (30 mL). The mixture was stirred at 25°C for 20 hours, poured onto ice and partitioned between 2N hydrochloric acid and ethyl acetate. The organic extracts were dried over magnesium sulfate, the solvent was evaporated under reduced pressure and the title compound purified by chromatography on silica gel, eluted with toluene, and crystallized from ethanol (4.1 g).

3. 2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno[2,3-b][1,5]-benzodiazepine

Methyl 2-(2-nitroanilino)-5-methylthiophene-3-carboxylate (3.7 g, 0.0013 mol) was hydrogenated in a Parr apparatus at 60 psi in ethanol-ethyl acetate (2:1, 150 mL) with palladium on charcoal catalyst (10%, 200 mg). After removal of catalyst and solvent the crude diamino-ester was dissolved in a mixture of N-methylpiperazine (21 mL) and anisole (55 mL). To this solution, under a nitrogen atmosphere was added, with stirring, a solution of titanium tetrachloride (3.45 mL) in anisole (15 mL). The mixture was stirred at 100°C for 1 hour, then under reflux for 48 hours to effect ring closure of 1-([2-(2-amino anilino)-5-methylthiophen-3-yl]carbonyl)-4-methylpiperazine.

After allowing to cool to 80°C a mixture of 30% ammonia solution (10 mL) and isopropanol (10 mL) was cautiously added, followed by ethyl acetate (25 mL). The inorganic precipitate was removed by filtration and the filtrate washed with water (3 x 25 mL), dried with magnesium sulfate and the solvent removed under reduced

pressure. The product was purified by chromatography on Florisil, eluted with ethyl acetate and finally crystallized from acetonitrile (40 mL) to give the title compound (2.32 g), identical with that described above.

EXAMPLE 3

A pulvule formulation is prepared by blending the active with silicone starch, and filling it into hard gelatin capsules.

	Per 300 mg capsule
Compound of the invention	5.0 mg
Silicone	2.9 mg
Starch flowable	292.1 mg

EXAMPLE 4

A tablet formulation is made by granulating the active with appropriate diluent, lubricant, disintegrant and binder and compressing

Compound of the invention	5.0 mg
Magnesium stearate	0.9 mg
Microcrystalline cellulose	75.0 mg
Povidone	15.0 mg
Starch, directly compressible	204.1 mg

EXAMPLE 5

An aqueous injection of active is prepared as a freeze-dried plug, for reconstitution in a suitable, sterile 25 diluent before use (to a total volume of 10 ml).

Compound of the invention Mannitol N
Hydrochloric acid and/or N sodium hydroxide to adjust pH to
5-5.5.

Compound of the invention	20.0 mg
Mannitol	20.0 mg
N Hydrochloric acid and/or N sodium hydroxide to adjust pH to 5-5.5.	

5

EXAMPLE 6

A controlled release injection for intramuscular
injection is formed from a sterile suspension of micronised
active in an oleaginous vehicle.

10

Compound of the invention	65.0 mg
Aluminium stearate	0.04 mg
Sesame oil	2 ml

EXAMPLE 7

A formulation is prepared by blending the active
with silicone starch and starch, and filling it into hard
gelatine capsules.

15

	Per 290 mg capsule
Compound of the invention	2.5 mg
Starch flowable with 0.96% silicone 220	217.5 mg
Starch flowable	70.0 mg


We Claim:

1. A method of treating a patient suffering from or susceptible to psychosis selected from the group consisting of Delirium, Organic Delusional Disorder, Multi-infarct demenia, with Delirium, Multi-infarct dementia, Uncomplicated, Multi-infarct dementia, with Delusions, Major Depression, Recurrent with Psychotic Features, and Organic Hallucinosiis comprising administering to a patient in need thereof an effective amount 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.

2. A method of Claim 1 wherein the effective amount is from 1 to 20 mg per day of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid addition salt thereof.

ABSTRACT OF THE INVENTION

2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-
[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has
pharmaceutical properties, and is of particular use in the
treatment of disorders of the central nervous system. The
compound has the following structure:



DECLARATION AND POWER OF ATTORNEY

Docket No.G-1265E

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first, and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the invention entitled

2-METHYL-THIENO-BENZODIAZEPINE

which is described and claimed in the specification which:

(check ☐) is attached hereto.

one) ☒ was filed on February 13, 1995
as United States Application Serial No. 08/387,997
or
PCT International Application No. _____
and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS
07/690,143	April 23, 1991	Abandoned
07/890,348	May 22, 1992	Issued
08/044,844	April 8, 1993	Abandoned
08/387,997	February 13, 1995	Issued

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

<u>Attorney</u>	<u>Reg. #</u>	<u>Attorney</u>	<u>Reg. #</u>
Brian P. Barrett	39,597	Jerry F. Janssen	29,175
Michael T. Bates	34,121	Robert E. Lee	27,919
Roger S. Benjamin	27,025	James P. Leeds	35,241
David E. Boone	27,857	Ronald S. Maciak	35,262
Margaret M. Brumm	33,655	Janet T. McClain	36,863
Steven P. Caltrider	36,467	Douglas K. Norman	33,267
Paul R. Cantrell	36,470	Arleen Palmberg	40,422
Daniel W. Collins	31,912	Kathleen R.S. Page	20,981
Robert A. Conrad	32,089	Thomas G. Plant	35,784
John C. Demeter	30,167	James J. Sales	33,773
Paul J. Gaylo	36,808	Janelle D. Strode	34,738
Edward P. Gray	30,638	Douglas J. Taylor	32,945
Amy E. Hamilton	33,894	Robert D. Titus	40,206
Martin A. Hay	39,459	MaCharri Vorndran-Jones	36,711
Thomas E. Jackson	33,064	Thomas D. Webster	39,872

said David E. Boone to have in addition the power to revoke the power granted to all others listed above.

Send Correspondence To:

Direct Telephone Calls To:
(name and telephone No.)

ELI LILLY AND COMPANY
Patent Division/DC 1104/MVJ
Lilly Corporate Center
Indianapolis, Indiana 46285

MaCharri Vorndran-Jones
317-276-1665

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Full Name of

First Inventor : Jiban Kumar Chakrabarti

Inventor's Signature : Jiban Kumar Chakrabarti Date: 15th May 1997

Residence Address : 3 Holly Hedge Road
Frimley, Camberley,
Surrey, England

Citizenship : United Kingdom

Full Name of Second
Inventor, : Terrence Michael Hotten

Inventor's Signature : Terrence Michael Hotten Date: 7th May 1997

Residence Address : 134 West Heath Road
Cove, Farnborough
Hants, England

Citizenship : United Kingdom

Full Name of Third
Joint Inventor, : David Edward Tupper


Inventor's Signature : David Edward Tupper Date: 6th May 1997

Residence Address : 8 Mildenhall Close
Lower Earley, Reading
Berkshire, England

Citizenship : United Kingdom

United States Patent & Trademark Office

Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

1. Application papers are not suitable for scanning and are not in compliance with 37 CFR 1.52 because:
 - ☐ All sheets must be the same size and either A4 (21 cm x 29.7 cm) or 8-1/2" x 11". Pages _____ do not meet these requirements.
 - ☐ Papers are not flexible, strong, smooth, non-shiny, durable, and white.
 - ☐ Papers are not typewritten or mechanically printed in permanent ink on one side.
 - ☐ Papers contain improper margins. Each sheet must have a left margin of at least 2.5 cm (1") and top, bottom and right margins of at least 2.0 cm (3/4").
 - ☐ Papers contain hand lettering.
2. Drawings are not in compliance and were not scanned because:
 - ☐ The drawings or copy of drawings are not suitable for electronic reproduction.
 - ☐ All drawings sheets are not the same size. Pages must be either A4 (21 cm x 29.7 cm) or 8-1/2" x 11".
 - ☐ Each sheet must include a top and left margin of at least 2.5 cm (1"), a right margin of at least 1.5 cm (9/16") and a bottom margin of at least 1.0 cm (3/8").
3. Page(s) _____ are not of sufficient clarity, contrast and quality for electronic reproduction.
4. Page(s) _____ are missing.
5. OTHER: NO Drawings